METABOLIC-FATE OF PARTIALLY DEPOLYMERIZED SHARK CHONDROITIN SULFATE IN MAN

被引:0
|
作者
RONCA, G [1 ]
CONTE, A [1 ]
机构
[1] UNIV PISA,INST BIOL CHEM,I-56100 PISA,ITALY
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Chondroitin sulfates and other glycosaminoglycans are administered as drugs to man by intravenous, intramuscular or oral routes. There are some studies on the pharmacokinetics of heparin, heparan sulfate and dermatan sulfate, whereas few data are available on the metabolic fate of chondroitin sulfate in man. Partially depolymerized chondroitin sulfate (mean mol. wt; 7.5 kd, range 5-10 kd) with a ratio of 1:3 between chondroitin-4-sulfate and chondroitin-6-sulfate has been administered as single administrations of 0.2 and 1.2 g by intramuscular and oral routes respectively to 10 healthy volunteers (5 males and 5 females), aging 25-53 years, After intramuscular administration the plasma level increased to a concentration peak at 90 min. The peak concentration, the elimination half-life and the apparent distribution volume were respectively 3.8 mcg/ml, 275 min and 0.40 ml/g. About 37% of the administered chondroitin sulfate is excreted in the urine during the first 24 h as high- and low-molecular-weight derivatives. After oral administration the concentration peak was observed at 240 min. The concentration at the peak, the elimination half-life and the apparent distribution volume were respectively 4.6 mcg/ml, 310 min and 0.44 ml/g. A peak of mono-, oligo- and polysaccharides with a molecular weight lower than 5 kd derived from partial digestion of exogenous chondroitin sulfate is also present in plasma. This study shows that about 10% and 20% of the orally administered drug is absorbed as high- and low-molecular-weight derivatives respectively. Comparison with the results obtained in experimental animals indicate that the metabolic fate of partially depolymerized chondroitin sulfate is similar in man and in experimental animals.
引用
收藏
页码:27 / 34
页数:8
相关论文
共 50 条
  • [21] STUDIES ON FATE OF NAPROXEN .2. METABOLIC-FATE IN VARIOUS ANIMALS AND MAN
    SUGAWARA, Y
    FUJIHARA, M
    MIURA, Y
    HAYASHIDA, K
    TAKAHASHI, T
    CHEMICAL & PHARMACEUTICAL BULLETIN, 1978, 26 (11) : 3312 - 3321
  • [22] METABOLIC-FATE OF BUFOTENINE-2-C-14 IN MAN
    SANDERSBUSH, E
    OATES, JA
    BUSH, MT
    FEDERATION PROCEEDINGS, 1975, 34 (03) : 809 - 809
  • [23] THE DISPOSITION AND METABOLIC-FATE OF C-14 MEROPENEM IN MAN
    HARRISON, MP
    HAWORTH, SJ
    MOSS, SR
    WILKINSON, DM
    FEATHERSTONE, A
    XENOBIOTICA, 1993, 23 (11) : 1311 - 1323
  • [24] METABOLIC-FATE OF PRAZOSIN
    TAYLOR, JA
    TWOMEY, TM
    VONWITTENAU, MS
    XENOBIOTICA, 1977, 7 (06) : 357 - 364
  • [25] METABOLIC-FATE OF DAIDZEIN
    YUEH, TL
    CHU, HY
    SCIENTIA SINICA, 1977, 20 (04): : 513 - 521
  • [26] THE METABOLIC-FATE OF THE ANTI-ANDROGENIC AGENT, OXENDOLONE, IN MAN
    MIDGLEY, I
    FOWKES, AG
    DARRAGH, A
    LAMBE, R
    CHASSEAUD, LF
    TAYLOR, T
    STEROIDS, 1983, 41 (04) : 521 - 536
  • [27] METABOLIC-FATE OF 14 GRISEOFULVIN-C-14 IN MAN
    LIN, C
    MAGAT, J
    CHANG, R
    SYMCHOWI.S
    PHARMACOLOGIST, 1973, 15 (02): : 228 - 228
  • [28] METABOLIC-FATE OF FELODIPINE IN MAN - IN SEARCH OF NEW DIHYDROPYRIDINE METABOLITES
    OHTAKE, Y
    SAKAMOTO, T
    NISHIOKA, R
    UNO, K
    TABATA, S
    DRUG INVESTIGATION, 1992, 4 (06): : 528 - 534
  • [29] DISPOSITION AND METABOLIC-FATE OF C-14 QUAZEPAM IN MAN
    ZAMPAGLIONE, N
    HILBERT, JM
    NING, J
    CHUNG, M
    GURAL, R
    SYMCHOWICZ, S
    DRUG METABOLISM AND DISPOSITION, 1985, 13 (01) : 25 - 29
  • [30] THE METABOLIC-FATE OF H-2-LABELED PROPAFENONE IN MAN
    HEGE, HG
    HOLLMANN, M
    KAUMEIER, S
    LIETZ, H
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 1984, 9 (01) : 41 - 55